ERBEVO is Ebola vaccine used in outbreak responses; current news centers on Congo's fastest Ebola outbreak and vaccine trials using Ervebo.
A UK-Oxford vaccine candidate has begun Phase I testing in healthy volunteers to assess safety and immune response. The work leverages the same technology as the Oxford–AstraZeneca Covid jab. Trials are planned in Africa with regional partners as the outbreak continues in the Democratic Republic of Congo.
The Bundibugyo-strain Ebola outbreak in eastern DRC has killed over 2,000 people amid more than 4,000 confirmed cases. WHO warns the outbreak could eclipse West Africa’s 2014-16 toll if access to affected communities does not improve. Vaccines and treatments remain limited, with trials under way and a push for a vaccine strategy.
The Democratic Republic of Congo has allocated 70,000 Ervebo vaccine doses from the global stockpile to respond to the Bundibugyo Ebola outbreak. Twenty thousand doses will support a Phase III trial on cross-protection against Bundibugyo, while 50,000 doses will protect frontline health workers. The outbreak is expanding across six provinces, with thousands of cases and deaths, and authorities are scaling up surveillance and vaccination efforts. WHO notes Ervebo is licensed for Zaire ebolavirus, not Bundibugyo, making the trial critical for evidence.